D.A. Diagnostics – Company Profile
- Industry: Health Care Providers & Services
- Primary Exchange: Shenzhen Stock Exchange (CNY)
- Market Capitalisation: 14.68 billion CNY
- Price‑to‑Earnings Ratio: –34.09 (negative earnings)
- Share Price (2026‑02‑10): 24.03 CNY
- 52‑Week Range: 12.36 – 33.30 CNY
D.A. Diagnostics Group Co., Ltd. is a third‑party independent medical laboratory operating in China. The company manages approximately 31 franchised laboratories and serves about 12,000 medical institutions. It has a collaboration agreement with Foundation Medicine, Inc. and F. Hoffmann‑La Roche Ltd. to integrate comprehensive genomic‑profiling assays into clinical care across mainland China. Founded in 2001 and headquartered in Hangzhou, the company was formerly Zhejiang DIAN Diagnostics Co., Ltd. and rebranded in November 2017. It is listed on the Shenzhen Stock Exchange with an IPO date of 19 July 2011.
News Update (as of 2026‑02‑12)
The most recent public filings and announcements available for D.A. Diagnostics are limited to routine regulatory disclosures that do not indicate a change in corporate strategy or significant financial events. No new earnings releases, board meeting outcomes, or strategic partnerships have been reported for the company in the timeframe examined. Consequently, there is no substantive news to report beyond the ongoing operations described above.
